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Abstract
Background: At least six host-encoded restriction factors (RFs), APOBEC3G, TRIM5α, tetherin, SAMHD1, schlafen 11,
and Mx2 have now been shown to inhibit HIV and/or SIV replication in vitro. To determine their role in vivo in the
resistance of macaques to mucosally-acquired SIV, we quantified both pre-exposure (basal) and post-exposure
mRNA levels of these RFs, Mx1, and IFNγ in PBMC, lymph nodes, and duodenum of rhesus macaques undergoing
weekly low dose rectal exposures to the primary isolate, SIV/DeltaB670.
Results: Repetitive challenge divided the monkeys into two groups with respect to their susceptibility to infection:
highly susceptible (2–3 challenges, 5 monkeys) and poorly susceptible (≥6 challenges, 3 monkeys). Basal RF and Mx1
expression varied among the three tissues examined, with the lowest expression generally detected in duodenal
tissues, and the highest observed in PBMC. The one exception was A3G whose basal expression was greatest in lymph
nodes. Importantly, significantly higher basal expression of TRIM5α and Mx1 was observed in PBMC of animals more
resistant to mucosal infection. Moreover, individual TRIM5α levels were stable throughout a year prior to infection.
Post-exposure induction of these genes was also observed after virus appearance in plasma, with elevated levels in
PBMC and duodenum transiently occurring 7–10 days post infection. They did not appear to have an effect on control
of viremia. Interestingly, minimal to no induction was observed in the resistant animal that became an elite controller.
Conclusions: These results suggest that constitutively expressed TRIM5α appears to play a greater role in restricting
mucosal transmission of SIV than that associated with type I interferon induction following virus entry. Surprisingly, this
association was not observed with the other RFs. The higher basal expression of TRIM5α observed in PBMC than in
duodenal tissues emphasizes the understated role of the second barrier to systemic infection involving the transport of
virus from the mucosal compartment to the blood. Together, these observations provide a strong incentive for a more
comprehensive examination of the intrinsic, variable control of constitutive expression of these genes in the sexual
transmission of HIV.
Keywords: APOBEC3G, TRIM5α, Tetherin, SAMHD1, Schlafen 11, Mx1, Mx2, Restriction factors, SIV, Mucosa
Background
Why certain individuals readily acquire sexually-transmitted
HIV, while others remain persistently uninfected des-
pite repeated exposure, has confounded scientists since
t h eb e g i n n i n go ft h eA I D Se p i d e m i c .S o m es t u d i e si n d i -
cate that differences in host genetics or virus-specific
immunity participate in virus control [1-3], but it is un-
likely that a single factor is responsible.
It is generally agreed that inhibition of virus replica-
tion in the mucosal compartment during the first seven
days after sexual exposure is the ideal time to prevent/
delay systemic infection [4,5] because the physical bar-
rier imposed by the vaginal and rectal epithelium creates
a genetic bottleneck whereby only a few infected cells
produce limited amounts of virus [5,6]. We, and others
[4], have hypothesized that a second, less studied, barrier
also exists that involves the transport of virus from the
mucosal compartment into the circulation via the in-
fected cell.
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lication of the founder population by upregulating type I
interferons that, in turn, induce a myriad of interferon-
stimulated genes (ISGs) to create an antiviral environ-
ment in nearby cells [7,8]. Among the ISGs that have
garnered significant attention because they directly in-
hibit HIV and/or SIV replication are a group of cellular
proteins called restriction factors (RFs). To date, six RFs
with activity against HIV and/or SIV have been identified
(TRIM5α, APOBEC3G (A3G), tetherin, SAMHD1, schla-
fen 11, and Mx2). Schlafen 11 (SCHL11) and Mx2 are the
most recent additions to the RF repertoire. More informa-
tion is necessary regarding SCHL11’s anti-HIV mechan-
ism [9] and its activity against SIV is as yet unknown.
Mx2 inhibits a wide range of primate immunodeficiency
viruses [10,11]. In general, RFs are species-specific and less
effective against native viral strains [12]. As a result, rhe-
sus macaque TRIM5α potently blocks HIV-1, thereby pro-
viding an explanation for the current inability to create an
HIV-1: rhesus macaque model [13]. These RFs are not
only induced by type I interferons during early infection,
they are also constitutively expressed in the naive host
[7,9,12,14-16]. Together, these RFs contribute to both the
intrinsic and innate defense against lentiviral infection.
Each RF has a different inhibitory activity within the
viral life cycle: A3G, TRIM5α, SAMHD1, and Mx2 pose
a post-entry block on the first stages of reverse tran-
scription and cDNA import, while SCHL11 and tetherin
inhibit viral translation and virion budding, respectively
[9,11-13,17-19]. Although currently debated, Mx2 ap-
pears to interfere with nuclear uptake of the virus repli-
cation complex and/or integration of viral cDNA [11].
However, both events appear to involve the viral capsid.
The importance of these RFs is evident by the co-
evolution of viral antagonists (vif, vpu/nef, vpx) that re-
spectively counteract A3G, tetherin, and SAMHD1. The
two exceptions are TRIM5α and Mx2. Evasion of
TRIM5α by SIV is accomplished by selecting mutations
in the N-terminus of the viral capsid containing the ma-
caque TRIM5α binding site [20-23], with specific muta-
tions at this site resulting in changes in binding affinity
[23,24]. While it is not currently known whether a viral
antagonist exists for Mx2, HIV-1 responds to Mx2 re-
striction by selecting for mutations in the capsid region
(A88) [25]. Interestingly, this activity is more potent in
nondividing cells [25].
Most of what is known about the activity of these RFs
on virus replication has been discovered by infection
studies in vitro [9,10,13,19,26,27]. However, an associ-
ation between expression of several RFs and viral infec-
tion/disease in vivo has also been observed. In one
study, HIV-exposed seronegative individuals had signifi-
cantly higher A3G levels in PBMC (peripheral blood
mononuclear cells) and cervical tissue when compared
to healthy controls [28]. A3G also may affect HIV-
induced disease progression because in another study,
the PBMC of long-term nonprogressors had significantly
higher A3G levels than those of non-controllers [29,30].
Higher pre-infection A3G levels were also found to in-
versely correlate with viral set point [31]. These findings
are further supported in rhesus macaques where higher
A3G expression was shown to correlate with lower virus
loads, increased survival, and protection from subse-
quent mucosal challenge [32,33].
The evidence for the role of tetherin in controlling
virus burden in HIV +humans is conflicting. Whereas
higher expression of tetherin was coupled to more rapid
disease progression in one study [34]; in another, induc-
tion of tetherin by IFNα treatment was associated with a
reduction in virus burden [35]. In macaques, transient
induction of tetherin was also observed that coincided
with viremia and induction of IFNα [36].
The association between TRIM5α expression and virus
infection has been best studied in SIV+macaques. Genetic
polymorphisms in the TRIM5α B30.2/SPRY domain re-
sponsible for binding to the viral capsid have been shown
to correlate with susceptibility to both infection and dis-
ease with some isolates of SIV but not others [24,37-40].
The direct impact of Schlafen 11, SAMHD1, and Mx2 in
controlling virus infection/disease in vivo in either system
has not yet been shown.
Although these studies support an important role for
RFs in the response to SIV/HIV infection and/or disease,
it is not clear whether the intrinsic and innate immune
response function independently or in a cooperative
fashion, and whether one or all of the RFs cooperate to
block virus transmission. A better understanding of how
the expression of these RFs affects the susceptibility to
mucosal exposure will be necessary to fully harness the
functions of these RFs for the development of effective
vaccines and therapeutics.
To address this issue, we subjected a cohort of eight
Indian origin rhesus macaques to weekly low dose rec-
tal challenges with the primary pathogenic isolate, SIV/
DeltaB670. Messenger RNA encoding the six RFs known
to affect SIV and/or HIV replication (TRIM5α,A 3 G ,
tetherin, SAMHD1, SCHL11, and Mx2), together with the
ISG Mx1 and IFNγ, was quantified in each animal prior to
and at 3-day intervals during the course of the challenges.
Although Mx1 has never been shown to be directly associ-
ated with inhibition of either HIV-1 or SIV, it is a well-
known marker of the type I IFN response and therefore
included in our assay [32,41].
Animals were divided into two groups (highly suscep-
tible and poorly susceptible) based on the number of
challenges required to induce a systemic infection. Both
basal (constitutive) and type I interferon-induced expres-
sion of these genes were compared in PBMC, inguinal
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relative association of tissue-specific RF expression to re-
sistance to mucosal challenge. This study provides pro-
vocative insight into the function of these RFs in
counteracting early virus infection in the mucosa and is
the first report of the SCHL11 and Mx2 response to pri-
mary SIV infection and their relationship to the other
ISGs in vivo.
Results
Outcome of repetitive low-dose rectal exposures
Eight Indian-origin rhesus macaques received up to 6 rec-
tal challenges at weekly intervals with 250-2500 TCID50 of
a primary stock of SIV/DeltaB670 until they became
viremic. The original source of this isolate was a Nigerian-
born sooty mangabey monkey (Cercocebus atys)w i t hn a t -
urally acquired leprosy that initiated the discovery of SIV
(see Additional file 1 for detailed viral lineage) [42,43]. For
further monkey studies, SIV/DeltaB670 was amplified
in vitro in rhesus PBMC (rhPBMC) with aTRIM5
CypA/CypA
haplotype. This haplotype, although fairly rare in a
homozygous state in rhesus macaques, fails to restrict
SIV/DeltaB670 replication, with virus growing to high
titers in vitro. Animals with this haplotype are aggres-
sively infected in vivo with peak virion RNA reaching
1×10
9/ml plasma during the acute viremic episode
followed by little reduction in titer (data not shown).
This stock is comprised of a complex genetic quasispe-
cies and is highly pathogenic in three species of ma-
caques [44-46].
Longitudinal analysis of the plasma virus burden in
these animals is shown in Figure 1. Despite the identical
stock/dose employed, the susceptibility to infection varied
widely among the animals. Five macaques had detect-
able viremia after 2–3 challenges (R700, R701, R702,
R703, R704; highly susceptible), while three macaques
required ≥6 challenges before virus was detected in the
plasma (R705, R697, R698; poorly susceptible). Once the
animals became infected, the viral set point also varied
widely among the animals, in a fashion surprisingly inde-
pendent of each animal’s susceptibility to infection.
Of particular interest is monkey R705. This animal de-
veloped a low-level transient viremia that was only de-
tected 17 days after the 6th low dose challenge. This
monkey was re-challenged rectally with a 100-fold higher
dose 72 days after the sixth challenge. Despite this dose,
the challenge was again followed by minimal transient
viremia. Recurrent blips in viremia without further rectal
exposures were detected thereafter, with a maximum of
100 copies/ml of plasma persistently detected only after
235 days into the study. In this aggressive model for AIDS,
this animal is considered an elite controller, as defined by
barely detectable, intermittent levels of virus in the plasma
without any other signs of infection or disease [47].
Altogether, these 8 animals displayed the full spectrum
of infection and disease previously described for SIV
[47-49], with 5 highly susceptible and 3 poorly suscep-
tible to infection following an identical dose/route of
virus exposure. Among these, and independent from
their susceptibility to infection, all animals except one
variably progressed to disease. The eighth animal (R705)
became an elite controller.
Tissue-specific basal ISG expression
Following sexual exposure, relatively few virions pass
through the barrier imposed by the mucosal epithelium
Figure 1 Outcome of repeated, low-dose rectal challenges with SIV/DeltaB670. Indian-origin rhesus macaques received weekly low dose
rectal challenges. Animals were challenged with 1cc of culture supernatant containing 250 TCID50 SIV/DeltaB670 for the first challenge and 2500 TCID50
for the remaining 5 challenges. Monkey 705 received a 7th challenge with 2.5 ×10
5 TCID50 72 days after the 6th challenge. Blood was collected twice
a week and copies of viral RNA were quantified in plasma by qRT-PCR using external standards. Animals were divided into two groups based on the
number of challenges required for systemic infection: highly susceptible (red); 2–3 challenges (R700, R701, R702, R703, R704) and poorly susceptible
(blue); ≥6 challenges (R697, R698, R705). Red dotted line at 10
4 viral RNA copies indicates the threshold virus load (VL) associated with clinical disease
in rhesus macaques infected with SIV/DeltaB670. Arrows indicate time points of challenge. Χ=sacrifice for tissue collection.
Aamer et al. Retrovirology 2014, 11:39 Page 3 of 17
http://www.retrovirology.com/content/11/1/39(6,000 times more infectiousS I V / D e l t a B 6 7 0v i r i o n s
are required to infect macaques intrarectally or intra-
vaginally than intravenously [50]). These establish in-
fectious foci in the rectal and vaginal submucosa [5,51]
to become the founder population. Following further
amplification, virus subsequently disseminates into the
bloodstream via the draining lymph nodes [5,52]. At
this point, virus has usually integrated into long-lived
resting CD4+ T cells and a persistent infection has been
established [53]. One goal of this study was to determine
the impact of both constitutive and type I interferon-
induced expression of RFs on this process. To address this
issue, we quantified both basal and induced expression of
A3G, TRIM5α, SAMHD1, tetherin, SCHL11, and Mx2
mRNA 4 days prior to and during the repetitive low dose
rectal challenges. Expression of Mx1, an ISG known for its
potent restriction of several viruses [41] and frequently
employed as a surrogate for type I Interferon induction
[32,54] was also analyzed. Quantitation of IFNγ mRNA
was also included to examine the impact of RF induction
on the adaptive immune response [16]. Three compart-
ments were examined: ficoll-paque purified PBMC, ILN,
and duodenal tissue obtained by biopsy.
As expected, mRNA for all of the ISGs was constitu-
tively expressed in all 3 tissues 4 days prior to virus expos-
ure (Figure 2). Tetherin and SAMHD1 were the most
abundantly expressed (Figure 2C,F) and SCHL11 was the
least expressed RF in all three tissues (Figure 2G). With
the exception of A3G, whose basal expression was higher
in ILN than the duodenum (P<0.01; Figure 2D) basal ex-
pression of the other ISGs was higher in PBMC than in
the duodenum (P<0.01). As expected for naive animals,
expression of IFNγ at all three sites was less than the other
genes (Figure 2H). A heat map of relative ISG expression
showed basal expression in PBMC and ILN to be more
similar than what was observed in the gut, and further
grouped the ISGs according to their similarities in expres-
sion (see Additional file 2). Importantly, a strikingly wide
range of animal-to-animal variation in the basal expres-
sion of these ISGs was observed that was particularly evi-
dent in PBMC. Together, these data illustrate that all the
ISGs were constitutively expressed in a tissue-specific
manner, with higher levels primarily found in PBMC.
Basal ISG expression and susceptibility to mucosal infection
To determine whether there was an association between
the basal level of ISG expression and the number of
times that an animal had to undergo repetitive challenge
to become persistently infected, the average relative ex-
pression prior to the first challenge from the two suscep-
tibility groups was statistically compared for each tissue
(Figure 3). Significantly higher expression of Mx1 and
TRIM5α mRNA was identified in the PBMC of animals
poorly susceptible to mucosal infection when compared to
that found in the highly susceptible group (Figure 3A,B).
These observations could not be explained by differences
in the SIV target cells (CD4+ T cells or monocytes) in the
PBMC of these animals because, although the absolute
numbers varied from animal to animal, the mean numbers
i nt h eh i g h l ya n dp o o r l ys u s c e p t i b l eg r o u p sw e r en o t
significantly different (data not shown). The mean basal
levels of tetherin, A3G, Mx2, SAMHD1, and Schlafen
11 were also higher in the PBMC of the poorly suscep-
tible group but these differences were not significant
(Figure 3C-G). In contrast, no significant difference was
observed in expression of any of the ISGs between the
two groups in either the ILN or duodenum. Even
though this analysis was performed on a limited sample
size, the magnitude of the observed differences seen for
TRIM5α and Mx1 is such that we have power >0.8 to
state that these significant differences are genuine,
based on determination of Cohen’s d as a measure of
the Effect Size (ES) seen [55].
The relationship between higher basal expression and
resistance to mucosal infection was further confirmed by
linear regression analysis. Basal ISG expression in each
tissue was plotted versus the number of exposures re-
quired for systemic infection (Figure 4). This analysis
yielded similar findings to that depicted in Figure 3. A
significant positive correlation was again observed in
PBMC for TRIM5α and Mx1 in addition to SAMHD1
and A3G (Figure 4A). This correlation was especially
strong for TRIM5α (r
2= 0.83, P =0.002). Interestingly,
despite the strong positive correlation between Mx1 ex-
pression and resistance to infection, this relationship
was not observed for Mx2. These results are intriguing
because, in contrast to Mx2, Mx1 has never been shown
to interfere with either HIV-1 or SIV infection. Linear
regression analysis further confirmed the lack of an asso-
ciation between basal expression of any of the ISGs in
ILN or duodenum and the number of challenges re-
quired to induce a systemic infection (Figure 4B,C).
Basal expression of TRIM5α is stable over time
As an initial attempt to determine whether the varying
levels of basal expression of TRIM5α observed among the
animals was constant within the individual, we compared
the levels of TRIM5α measured 4 days prior to virus expos-
ure to those collected 1 month and 11 months earlier. A
comparison of the relative TRIM5α mRNA levels measured
4, 26–33, and 289–298 days prior to the first challenge are
shown in Figure 5. At each time point, TRIM5α levels were
significantly higher in the poorly susceptible animals com-
pared to those that were highly susceptible. Furthermore,
basal TRIM5α levels did not significantly vary over time for
each animal (data not shown). These data suggest that basal
TRIM5α expression is stable over time at levels that appear
to be an intrinsic property of the host.
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http://www.retrovirology.com/content/11/1/39Figure 2 Basal ISG expression in PBMC, ILN and duodenum. Relative mRNA levels of (A) Mx1, (B) TRIM5α, (C) Tetherin, (D) A3G, (E) Mx2,
(F) SAMHD1, (G) SCHL11, and (H) IFNγ was determined in PBMC, inguinal lymph node mononuclear cells (ILN), and duodenal tissue biopsies of
the eight macaques. All samples were obtained 4 days prior to the first exposure (basal levels) on all animals except monkey R700 from which
PBMC samples were obtained on day 0 (day of first exposure). NormFinder [64] was used to determine the most stable endogenous control
(TBP, HPRT, β2M, βGus) among the three tissues. All gene expression values were normalized to TBP, the most stable endogenous control.
Relative expression was determined using the ΔCt method and the following formula: 1000 x 2
-ΔCt. Horizontal lines denote mean expression
levels in each tissue. Each symbol indicates the mean expression value for one animal. Significance was calculated using the Friedman test with
Dunn's multiple comparison test. Asterisks indicate significance at P<0.05.
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points and unlike TRIM5α, levels varied over time
among individual animals and significant differences be-
tween the poorly and highly susceptible groups was only
seen at the day −4 time point (data not shown).
Innate immune induction of RFs following virus exposure
We next sought to determine whether variable timing
and/or the magnitude of RF induction by virus exposure,
both of which could be controlled by intrinsic properties
of the host, were associated with the differences in the
Figure 3 Statistical analysis of basal ISG expression and susceptibility to infection. Relative basal mRNA levels of (A) Mx1, (B) TRIM5α,
(C) Tetherin, (D) A3G, (E) Mx2, (F) SAMHD1, (G) SCHL11 were measured in the PBMC, ILN, and duodenum of the eight macaques, highly susceptible
(R700-R704) and poorly susceptible animals (R697, R698, R705). Levels of basal ISG expression for each group were calculated as described in Figure 2.
Each symbol indicates the mean expression value for one animal. Significance was calculated by the Mann–Whitney test. Asterisks indicate significance
at P < 0.05.
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IFNγ expression was measured in PBMC at 3-day inter-
vals during the series of 6 challenges, and in the duode-
num 3 days after the first 3 mucosal challenges for each
animal. Fold change was determined by dividing relative
mRNA levels at each time point with those at baseline
(day −4 of the challenge series), with a 2 fold change
serving as the minimum threshold for induction.
The fold change in ISG and IFNγ expression in
PBMC, plotted in relation to plasma virus loads, is
shown in Figures 6, 7 and 8. As expected for their role
as ISGs, induction of all RFs was observed in most of
the animals, with Mx1 and Mx2 expression achieving
the highest levels. Induction of these genes was transi-
ent, however, and detectable only after virus appearance
in the blood. Interestingly, in the highly susceptible
monkeys, a transient rebound in Mx1 and Mx2 induc-
tion occurred that corresponded with modest increases
in plasma virus burden suggesting that several waves of
virus production had occurred (Figure 6).
Inexplicably, the pattern of ISG induction varied widely
among the 3 animals that required ≥6 challenges to
Figure 4 Linear regression analysis of basal RF expression and resistance to infection. Basal ISG mRNA levels in (A) PBMC, (B) Duodenum,
(C) ILN were calculated as described in Figure 2 and plotted versus the number of exposures required for systemic infection. Each dot indicates
mean expression value of one animal. Lines depict linear regression analysis with r
2 and P values indicated next to each gene. Asterisks indicate
significance with P< 0.05.
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although a transient, modest (<8 fold) induction of Mx1
and Mx2 was observed in monkey R698 in response to
virus in the circulation (Figure 7B), a 60–150 fold induc-
tion of Mx2 expression was observed in monkey R697 that
persisted throughout the maintained high plasma virus
burden of 1×10
5 RNA copies/ml plasma (Figure 7A).
Perhaps the most striking deviation from the pattern
observed in persistently infected animals was detected in
the elite controller monkey R705 (Figure 8). Expression
of the RFs remained unchanged despite the repetitive
challenges and transient viremic episodes, with induc-
tion levels remaining below the 2-fold threshold. Induc-
tion of Mx1 and Mx2 alone was observed at a single
time point during the first viremic blip (days 52–63), but
this barely achieved the threshold. Induction of IFNγ
eventually occurred 205 days into the study that corre-
sponded with the return of virus in the plasma.
ISG induction in the duodenum
Although analysis of ISG expression in PBMC was sur-
prisingly revealing, we argued that analysis of the re-
sponse of these genes to incoming virus in the mucosa
should tell us more. Although the rectal pouch is the
physical site of viral entry, mucosal tissues of the duode-
num were biopsied to avoid interference with the weekly
rectal challenges. We reasoned that, with the exception
that the rectal pouch is more enriched for Peyer’s-like
patches than the remaining gut [56], the cellular com-
position of the gut is similar throughout, with cells in a
constant flux of recently activated cells migrating from
and mature effector cells returning to the gut via the
lymphatics and blood. Thus, both sites (duodenum and
rectum) should behave similarly. To assure the validity
of these assumptions with respect to ISG induction, we
analyzed expression in both duodenal and rectal biopsies
3 days after the 6th challenge of the one monkey that
remained uninfected after 6 challenges (monkey R705).
A comparison of the values obtained from these tissues
showed no significant differences in expression of any of
the ISGs in the two mucosal tissues despite the transient
appearance of virus in the circulation that followed the
6th challenge (data not shown).
We quantified ISG expression in the duodenum 3 days
after the first 3 weekly challenges in all the animals. We
discontinued collection of duodenal biopsies after 3
challenges to avoid affecting the health of the animal. A
detailed longitudinal examination of ISG induction in
the duodenum during the first 3 challenges is shown for
the animals that became infected within this timeframe
to determine whether ISG induction differed in the gut
and blood (Figure 9). The timing and pattern of induc-
tion in the duodenum was similar to that observed in
PBMC (Figure 6) with two notable exceptions: (1) In
two animals (monkeys R701 and R702), a transient, se-
lective induction of Mx1 (5–8 fold) was observed in the
duodenum 3 days following the first challenge that was
not associated with subsequent viremia, and (2) Induc-
tion of Mx1 in the gut of 2 of these animals (monkeys
R700 and R701) during viremia was almost 3 times
greater than that observed in PBMC at the same time
point. ISG induction on day 3 in the duodenum but not
PBMC suggests that a transient mucosal infection had
occurred in these animals that failed to disseminate to
the periphery. The patterns observed in the duodenum
for the rest of the cohort over the first 2 challenges
Figure 5 Basal TRIM5α mRNA levels over time. Relative basal mRNA levels of TRIM5α was measured 4, 26–33, and 289–298 days prior to the
first challenge and plotted for the highly susceptible (R700-R702, R704) and poorly susceptible animals (R697, R698, R705). Values for R703 were
omitted due to lack of sample at all 3 time points. GeNorm analysis by the GenEx 6 MultiD software (TATA Biocenter, Sweden) chose TBP and
βGus as the most stable genes and all gene expression values were normalized to them using the ΔCt method and the following formula: 1000 × 2
-ΔCt.
Significance was calculated by 2way ANOVA with Sidak’s multiple comparison test. Asterisks indicate significance at P < 0.05. The magnitude
of the observed differences seen for TRIM5α is such that we have power >0.8 to state that these significant differences are genuine, based on
determination of Cohen’s d as a measure of the Effect Size (ES) seen [55].
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because a transient mucosal infection did not occur in
these animals at these time points (data not shown).
Discussion
The discovery that an array of restriction factors have
co-evolved with HIV/SIV to synergistically block replica-
tion at various stages of the viral life cycle, and the ap-
parent ability that at least two of these play in blocking
cross-species transmission [24,57], supports the argu-
ment that a complex system is likely required to limit
transmission and control disease within the natural host.
The power of these RFs is two-fold: (1) they are consti-
tutively expressed in the immune cells targeted by HIV/
SIV, thereby allowing them to function at the moment of
infection as intrinsic defense proteins, and (2) they are
induced by type I interferons, a function that renders
them members of the interferon-stimulated gene family
that are essential components of the innate immune
system [12,17,22,58]. Together, these functions form syn-
ergistic intrinsic and innate immune weapons of defense
against mucosal invasion.
Despite the current knowledge of the function of these
RFs in HIV/SIV infection in vitro, little is known about
the potential role of these genes in controlling virus in-
fection in vivo. Moreover, few studies have thoroughly
evaluated the role of basal RF expression on the suscep-
tibility to HIV/SIV infection. In this report we describe
constitutive (basal) and type I interferon-induced mRNA
expression of all 6 known lentiviral RFs (A3G, TRIM5α,
tetherin, SAMHD1, Schlafen 11, and Mx2), in addition
to another ISG with antiviral properties, Mx1, in a group
of macaques undergoing repetitive low dose rectal expo-
sures with the primary isolate, SIV/DeltaB670. The series
of weekly low dose rectal challenges resulted in the full
range of susceptibility to infection commonly observed
for SIV [48,49], with 5 monkeys becoming systemically
infected after 2–3 exposures, while 3 monkeys became
(See figure on previous page.)
Figure 6 ISG induction in PBMC of macaques highly susceptible to infection. The fold change in the relative expression of each RF, Mx1,
and IFNγ post-exposure are plotted for susceptible animals (A) R700, (B) R701, (C) R702, (D) R703, (E) R704. Each gene is depicted by a different
colored bar as indicated in the figure legend. Plasma virus loads (VL) are shown by the black line. All samples were obtained 4 days prior to the
first exposure (basal levels) on all animals except monkey R700 from which PBMC samples were obtained on day 0 (day of first exposure). Fold
change in gene induction was calculated by dividing the relative mRNA level at each time point by the basal level obtained prior to first rectal
challenge. Values were normalized to the endogenous controls TBP and HPRT. The black horizontal line at a 2-fold change indicates the threshold
for the observed induction to be true. Asterisks next to day numbers indicate days of rectal challenge.
Figure 7 ISG induction in PBMC of macaques poorly susceptible to infection. The fold change in the relative expression of each RF, Mx1,
and IFNγ are plotted for resistant animals (A) R697, (B) R698 as described in Figure 6.
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tion resulted in widely variable disease progression pat-
terns that ranged from rapid, immediately progressive
disease to elite control. Although the study group con-
tained only 8 monkeys, we reasoned that the balanced
diversity in outcome at both levels (transmission and
disease) in these animals provided a sound platform with
which to examine the contribution of basal and type I
interferon-induced RF expression to both.
As expected, all the RFs were constitutively expressed
in the animals in PBMC, inguinal lymph nodes, and
duodenum prior to exposure. Significant differences in
tissue-specific expression were observed, however. Basal
levels of all RFs were notably higher in PBMC than in
the mucosa, with the exception of A3G, which was more
highly expressed in ILN than in PBMC. Strikingly, al-
though maximal relative expression after virus exposure
was similar in the PBMC of all eight monkeys, the basal
expression of these RFs prior to exposure varied signifi-
cantly. Statistical analysis of these differences demon-
strated that animals more resistant to mucosal infection
(≥6 exposures required to establish a systemic infec-
tion) had significantly higher basal mRNA levels of
TRIM5α and Mx1 in PBMC than highly susceptible an-
imals (2–3 exposures required to establish a systemic
infection). Interestingly, this association was observed
only in PBMC and not the duodenum or ILN. More-
over, the variable basal levels of TRIM5α,b u tn o tM x 1 ,
were held constant with respect to each individual dur-
ing the year prior to the study, a finding that suggests
that control of basal TRIM5α expression is intrinsic
to the host. Whether these differences can be genetic-
ally explained (e.g., polymorphisms in the TRIM5α
promotor region or variation in gene copy number) is
currently under study.
Interestingly, our findings are supported by several
studies in HIV-exposed humans. Perhaps the most
provocative finding was reported in 2009 where a
similar analysis of the CAPRISA acute infection co-
hort demonstrated that PBMC of individuals who
remained uninfected had significantly higher basal
levels of TRIM5α mRNA at the study start than the
PBMC of individuals who subsequently became HIV-1
infected [59]. Higher expression of A3G was also
identified in PBMC of exposed uninfected humans
than that found in the general population [28,29], but
whether this increase was an inherent characteristic
of the host or virally-induced was not determined.
Our data provocatively suggest that TRIM5α may
potentially affect mucosal transmission of SIV/HIV
under the following conditions: (1) Because basal
TRIM5α expression in individuals more resistant to
infection is higher in target cells at the time of ex-
posure, it may be effective in interfering with the
first rounds of early infection (2) However, induction
by type I interferons after virus entry appears too lit-
tle too late; indeed, these events may promote acti-
vation and recruitment of target cells to thereby
enhance infection [4], and (3) The target cells that
provide the critical barrier to infection may not be
those that block virus entry and/or allow initial ex-
pansion in the mucosal compartment [4], but, rather,
those responsible for the dissemination/expansion of
virus from the mucosal compartment to the blood-
stream. That a marker for susceptibility/resistance to
low dose mucosal exposure resides in PBMC rather
Figure 8 ISG induction in PBMC of the elite controller. The fold change in the relative expression of each RF, Mx1, and IFNγ are plotted for
the elite controller, R705, as described in Figure 6.
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vide an ideal source for confirming our observations
in other macaque and human studies using cryopre-
served samples.
It is perhaps noteworthy that because maximum
ISG expression levels were essentially the same in all
animals, the fold induction calculated as the max-
imum level over baseline, was associated with animals
more susceptible to infection (e.g.; they had lower
basal expression). Thus, in the highly susceptible ani-
mals, lower basal expression may additionally provide
a greater change in the immune environment in re-
sponse to innate immune induction, thereby allowing
greater activation and recruitment of target cells [4].
Conversely, in the elite controller, induction of only
Mx2 was detected at a single time point during the
first viremic blip. This animal never achieved a virus
burden consistent with progressive disease, despite
the 100-fold higher dose used as a final challenge.
The cause for the failure to respond to virus exposure
in this animal is unknown, but is perhaps a critical
point for further consideration.
Mx1 induction in the blood was also highest in the
highly susceptible animals (7–50 fold), while poorly
susceptible (R697, R698) only exhibited a 4–15 fold in-
crease. This finding is consistent with another report
of persistently higher Mx1 expression in progressor
macaques while little to no Mx1 expression was de-
tected in nonprogressors [54]. Indeed, Mx1 mRNA
levels appear to be a reliable indicator of ongoing virus
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Figure 9 ISG induction in the duodenum during early challenges. The fold change in the relative expression of each RF, Mx1, and IFNγ are
plotted for the duodenum of animals that became infected during the first 3 challenges (A) R700, (B) R701, (C) R702 as described in Figure 6.
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fected macaques strongly correlating with increased
plasma virus load [54]. The coordinate induction of
Mx1 and Mx2 and high virus loads observed in our
study is also supported by earlier studies showing per-
sistent IFNα production causing a heightened level
of immune activation and T cell apoptosis, thereby fa-
cilitating further virus replication and disease progres-
sion [16].
Selective induction of Mx1 and Mx2, but not the
other RFs, in several of these animals suggests that
different cell types or activation pathways may be in-
volved. For example, pDCs in the circulation may have
been exposed to free virus particles/proteins either dir-
ectly by the challenge virus or produced by a limited
infection in the mucosal compartment that transiently
appeared as free virions in the circulation to selectively
activate Mx1 and Mx2. In contrast, induction of the
other RFs may require the help of cellular proteins
within the infected cell.
Induction of Mx1 in the gut but not the blood of 2 of
the highly susceptible animals following the first failed
challenge is consistent with a localized infection that
was contained within the mucosal compartment. These
observations suggest that induction of Mx1 may provide
an important signal for the transient presence of virus in
the mucosal compartment that fail to establish a
productive infection. Whether free virus or the virus-
infected cell was subsequently cleared by cells respond-
ing to incoming virus or carried to reservoirs to establish
a latent infection is unknown at present.
Coordinate induction of RFs was observed in response
to systemic infection in animals highly susceptible to in-
fection. This innate response was transient, however,
and appeared to be overwhelmed by the tidal wave of
virus as it disseminated throughout the body. Similar to
other studies [60], induction of the RFs reported here
seemed to be a marker of virus replication, rather than
an inhibitor. This is further supported in a study exam-
ining HIV-1 infected human donor cells where antiviral
gene induction did not necessarily correlate with lower
virus loads [61].
Important questions are brought to light by our obser-
vations that remain unanswered. First, although the
stable basal expression of TRIM5α observed in animals
suggested that control of constitutive expression is in-
trinsic to the host, could the basal TRIM5α levels be af-
fected by prior insult to the immune system with an
unrelated pathogen? In a recent study in macaques, vari-
able frequencies of α4β7
high memory CD4+ T cells were
identified in both the blood and gut-associated lymphoid
tissue of macaques [62]. Higher populations of these
cells correlated with an enhanced susceptibility to muco-
sal infection and higher acute virus load, presumably
due to the increase in target cells at the site of mucosal
exposure. α4β7 T cell populations fluctuated over time
in the tissues, however, with high levels at exposure cor-
relating with susceptibility to infection, whereas those
present months earlier did not. Whether this observa-
tion relates directly to our own requires further study.
Second, are the same cells responsible for constitutive
and type I Interferon-induced expression? If so, what dif-
ferentially regulates the two? How is this tied in with
basal Mx1 (but not Mx2) expression? Are the same tar-
get cells critical to mucosal infection found in PBMC
also present in the mucosal compartment but in insuffi-
cient numbers to have an inhibitory effect? Single cell
isolation and detailed analysis of cells infected in vivo
will be required to address these questions.
Third, at what level do TRIM5 polymorphisms play
in our observations? Although differences in the
TRIM5α capsid binding site known to control infec-
tion with other SIV isolates have no apparent effect in
the studies with SIV/DeltaB670 reported here (unpub-
lished) and elsewhere [45], do other polymorphisms,
perhaps in the promoter regions that control expres-
sion, or variable gene copy number, have an effect?
Complete genome sequencing of these animals is un-
derway to address this issue.
While our study has begun to shed light on an import-
ant aspect of intrinsic immunity and resistance to infec-
tion, there are limitations in our study that are worth
highlighting. Although power analysis confirmed our
study had an adequate number of animals in the highly
and poorly susceptible groups to assure that our obser-
vations were valid, additional cohorts of similarly ex-
posed macaques are needed to strengthen our findings.
Indeed, although the response to low dose exposure in
both vaginal and rectal mucosal lamina propria should
be similar, will the vaginal epithelium under strict hor-
monal control override these events? The data from the
CAPRISA study [59] suggest not, but more detailed
studies in macaque trials employing vaginal challenge
should address this issue. Finally, although we emphasize
that the results described in this report are preliminary,
they should serve as an important player in guiding fu-
ture work in the area of the role of lentiviral restriction
factors in sexual transmission.
Conclusions
In summary, analysis of the intrinsic basal and innate
immune induced expression of the known lentiviral re-
striction factors prior to and during low dose repetitive
mucosal challenge with SIV in macaques provided the
following salient observations to direct future studies:
1. High constitutive (basal) expression of TRIM5α in
PBMC, but not gut and lymph nodes, significantly
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of a primary isolate of SIV.
2. Basal expression of TRIM5α remained constant
within the individual, suggesting that control of
basal TRIM5α expression is intrinsic to the host.
3. Innate immune induction of RFs in PBMC and
duodenum was transient and appeared to be too late
to have a major impact on mucosal infection in vivo.
4. In contrast to previous studies showing the
inhibitory potential on HIV/SIV replication, Mx2
induction had no apparent control on virus levels
in vivo.
Methods
Ethics statement
Eight Indian-origin rhesus macaques, 4 female and 4 male,
ranging in age from 3 to 7 years were obtained from an ap-
proved vendor (Three Springs Scientific, Perkapsie, PA).
The animals were housed and provided environmental
enrichment in accordance with “The Use of Nonhuman
Primates in Research” and the guidelines of the Associ-
ation for Assessment and Accreditation of Laboratory
Animal Care International (AAALAC) with the approval of
the University of Pittsburgh's Institutional Animal Care
and Use Committee (Assurance number A3187-01) stan-
dards/regulations (Protocol number 1006470). Studies were
conducted according to the principals described in The
Guide for the Care and Use of Laboratory Animals. Ani-
mals were cared for by competent veterinary and animal
caretaker staff, fed twice daily and provided daily enrich-
ment. All experimental procedures were performed under
ketamine anesthesia and any discomfort or pain was allevi-
ated by appropriate use of analgesic agents at the discretion
of the veterinarian. Animals were monitored monthly for
signs of disease such as weight loss, respiratory disease and
evidence of opportunistic infections. Humane euthanasia
was performed in accordance with guidelines as established
by the 2007 American Veterinary Medical Association
Guidelines on Euthanasia either for tissue collection or
once manifestation of clinical AIDS or signs of fatal disease
were observed.
Viral challenge
Each animal was rectally challenged on a weekly basis
with 1mL cell free SIV/DeltaB670 (250–2500 TCID50).
Briefly, sedated animals (10 mg/kg Ketamine i.m.) were
positioned in sternal recumbence and inoculated via
atraumatic insertion of a 3-ml syringe (lubricated with
Surgilube®) approximately 5 cm into the rectum. The in-
oculum was contained in 1.0 ml of saline. The inocula-
tion was slowly pushed in for a full minute; the syringe
left in place for 5 minutes and the animal left in sternal
recumbence for a total of 15 minutes. Animals were ini-
tially challenged with 250 TCID50 of the SIV/DeltaB670
stock but were challenged with 10-fold more virus (2500
TCID50) for the remaining 5 challenges. Monkey 705 re-
ceived a 7th intrarectal challenge with 2.5 × 10
5 TCID50.
Challenges were terminated when virus was detectable
in the plasma. Blood (3-10 mLs) was collected twice a
week from each animal.
Sample collection
Duodenal biopsies were obtained endoscopically 4 days
prior to each of the first three rectal challenges and 3 days
later, collected in 1 mL TRIzol, and stored at −80°C.
Inguinal lymph nodes (ILN) were surgically removed at
these same time points and immediately processed for
mononuclear cell purification. 15–18 pinch biopsies of the
rectal vault were obtained 4 days prior to the 6th rectal
challenge and 3 days later in Monkey R705. The duode-
num was specifically sampled due to accessibility by an
oral endoscope, ease of sampling without causing harm to
the animal, and relevance to understanding mucosal re-
sponse to SIV infection. The ILN was specifically obtained
due to the location and ease of repetitive removal without
surgery.
Plasma virus loads
Viral RNA was extracted from plasma using TRIzol
(Ambion) and RT-PCR was performed as previously de-
scribed using primers specific for the viral long terminal
repeat [63]. RT-PCR was performed on a Prism 7700
(Applied Biosystems) using external standards with an
8-log range. Final values were extrapolated from the
standard curve and were expressed as RNA copies/ml
plasma. Sensitivity threshold for this quantitative assay
was ~50 copies.
MNC purification
PBMC were isolated by Ficoll-Paque (Pharmacia) density
barrier centrifugation from rhesus macaque blood sam-
ples treated with ACD and were either viably frozen in
liquid nitrogen or pelleted and frozen at −80°C. Mono-
nuclear cells (MNC) were isolated from inguinal lymph
nodes by teasing and soaking in 10% RPMI 1640 [sup-
plemented with 15% fetal bovine serum, penicillin-
streptomycin (100 U/mL), L-glutamine (2 mM), HEPES
buffer solution (10 mM)] followed by straining to obtain
purified mononuclear cells. After several washes with
10% RPMI, purified MNCs were viably frozen in liquid
nitrogen.
Cellular RNA extraction
Total RNA was isolated from viably frozen PBMC/ILN
or frozen PBMC pellets using TRIzol (Ambion). RNA
was isolated from the duodenal biopsies by first grinding
the tissue with disposable tissue grinders and adding
1mL TRIzol. The Turbo DNA-free kit (Ambion) was
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concentration was measured on the 2000c Nanodrop
spectrophotometer (Thermo Scientific) and RNA purity
and integrity was verified using the RNA 6000 Pico kit on
the Agilent 2100 Bioanalyzer (Agilent Biotechnologies).
RF Expression assays
A maximum of 2ug total cellular RNA was reverse tran-
scribed using the High Capacity cDNA Reverse Tran-
scription kit (Applied Biosystems). A total of 25 ng
cDNA was used for RT-PCR amplification of each gene
and reactions were performed in duplicate. Positive con-
trols and no template controls were included in each
assay. Each assay was specific for rhesus macaques and
amplified exon-exon regions and did not detect genomic
DNA. RT-PCR was performed on the 7900 HT Fast
Real-time PCR system (Applied Biosystems) using the
recommended reagents (Taqman Fast Universal PCR
Mastermix 2×, no AmpErase UNG-Applied Biosystems)
and conditions supplied with the Taqman assays. Reac-
tion protocol: 10 uL 2× Mastermix, 1 uL 20× Taqman
gene expression assay, 8 uL water, 1 uL 25 ng cDNA. The
following are the Applied Biosystems Taqman assay IDs:
A3G: Rh02788475_m1, TRIM5α: Rh02788631_m1, Tetherin:
Rh02848328_m1, SAMHD1: Rh01122752_m1, Schlafen 11:
Rh02885088_m1, Mx1: Rh02842279_m1, Mx2:Rh02842285_
m1, IFNγ: Rh02788577_m1, TBP: Rh00427620_m1, HPRT:
Rh02827360_m1, β2M: Rh02847367_m1, βGUS: Rh02788
764_m1. Since the listed TRIM5α assay detected exons 7–8,
which is absent in the TRIMCypA allele in one macaque
(R701), we used another TRIM5 probe (Rh02788626_m1)
that detected exons 1–2, a non-polymorphic site in both
TRIM5α and TRIMCypA. Relative TRIM5 expression levels
from both TRIM5 probes showed minor differences and
therefore only the TRIM5α probe that detected exon 7–8
was used throughout the study.
All genes were validated for efficiency prior to the start of
the assay by creating serial dilutions of a control cDNA
sample (see Additional file 3). Linear regression analysis
was performed to evaluate assay linearity (R
2) and efficiency
(1–10
-1/slope). All lines had R
2 values >0.99 indicating lin-
earity. Slopes were between −3.3 and −3.6 and therefore ef-
ficiency was >90%. A total of four endogenous controls
were used at the start of the assay (TBP, HPRT, β2M, βGus)
to determine the most stable genes. Raw RT-PCR data was
analyzed first by SDS RQ manager (version 2.3, Applied
Biosystems) to obtain the Ct values. DataAssist Software
(Applied Biosystems, version 3.01) and NormFinder [64]
were used to determine the most stable housekeeping genes
and to calculate the 2
-ΔCt values. Relative gene expression
was determined by the following formula: 1000×2
−ΔCt.
Fold change in expression was calculated by dividing the
relative expression at each time point by the basal expres-
sion (four days prior to the first challenge).
Statistical analysis
Statistical analysis was performed using Prism 6.0b for
Mac OS X and the appropriate statistical tests were
listed under each figure. P <0.05 was considered signifi-
cant. The statistical power available to us was deter-
mined by calculating Cohen’s d as a measure of the
Effect Size (ES) of our comparisons [55]. The power was
then determined using G*Power software [65].
Additional files
Additional file 1: Lineage of the SIV/DeltaB670 challenge stock and
relationship to SIVsmE660. Both SIV/DeltaB670 and SIVsmE660 were
derived from sooty mangabey monkey A022 (green box) that was
infected by intravenous and subcutaneous inoculation with lepromatous
leprosy homogenates from a sooty mangabey monkey with naturally
acquired leprosy born in Nigeria (SM A015; white box). Blue boxes
indicate monkey-to-monkey passage of SIV/DeltaB670; orange boxes
indicate passage of SIVsmE660. Boxes outlined in red indicate a virus
isolate. Each arrow indicates virus passage in vivo in a monkey or
in vitro in PBMC. Animal numbers are noted for each passage. The
known TRIM5 genotype (CypA/CypA) is noted for RM J943 and RM
R245. The TRIM5 genotype is unknown for the other monkeys. SM:
sooty mangabey, RM: rhesus macaque, LN: lymph node.
Additional file 2: Heat map analysis of basal tissue-specific RF, Mx1,
and IFNγ expression among animals. Basal gene expression was
measured in duodenal biopsies (gut), peripheral blood mononuclear cells
(PBMC) and inguinal lymph node mononuclear cells (ILN). All samples
were obtained 4 days prior to the first exposure (basal levels) on all animals
except monkey R700 from which PBMC samples were obtained on day
0 (day of first exposure). Heat map analysis was performed using GenEx
software from MultiD (TATA Biocenter,S w e d e n ) .R e l a t i v eq u a n t i t y( R Q )
values were calculated from ΔCt values using the formula 1000 × 2
-ΔCt.
Heat Maps for gene expression were generated from log2 values. RQ values
were converted to log2 values in GenEx. To classify genes based on
expression profiling, log2 values were autoscaled for heat map analysis.
Additional file 3: Validation of the linearity and efficiency of
Taqman Gene Expression assays. PBMC cDNA was serially diluted and
amplified using pre-developed Taqman Gene Expression assays (Applied
Biosystems) and the corresponding Cq (quantification cycle) was plotted
at each cDNA concentration. Linear regression analysis was performed to
evaluate assay linearity (R
2) and efficiency (1–10
-1/slope). All lines had R
2
values >0.99 indicating linearity. Slopes were between −3.3 and −3.6 and
therefore assay efficiency was >90%.
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